Search
Clioquinol
go.drugbank.com/drugs/DB04815ApprovedVet approvedWithdrawnClioquinol was withdrawn in 1983 due to neurotoxicity.
Mixtures: Phen-oris - Ont TopAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalIt is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to
Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedSince July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients … Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity
Xanthinol
go.drugbank.com/drugs/DB09092ApprovedWithdrawn[L1079] Xaninthol is known to be a potent vasodilator that can easily pass through the cell membrane and once inside the cell it causes an increase in glucose metabolism resulting in an increased energy
Cimetidine
go.drugbank.com/drugs/DB00501ApprovedInvestigationalA histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions.
Ichthammol
go.drugbank.com/drugs/DB11341ApprovedIchthammol is also referred to as ammonium bituminosulfonate or ammonium bituminosulphonate. … It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic … receptors as opposed to dopamine receptors.
Interferon alfa-2a
go.drugbank.com/drugs/DB00034ApprovedInvestigationalWithdrawnAn oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnSerdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome